Presentations DateTitle May 01, 2022 ARVO 2022 Poster: Results of a Phase 1b clinical trial of KPI-012, a novel secretome therapy, in participants with Persistent Corneal Epithelial Defect (PCED) 625.7 KB Apr 25, 2022 Kala Corporate Overview - April 2022 3.6 MB Nov 15, 2021 KPI-012 Overview Presentation 640.9 KB
ARVO 2022 Poster: Results of a Phase 1b clinical trial of KPI-012, a novel secretome therapy, in participants with Persistent Corneal Epithelial Defect (PCED) 625.7 KB